Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Reserpine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A2 known ✓ | Q05940 | 1/20 | 0.99 |
| ▸ | MEN1 | O00255 | 12/20 | 0.99 |
| ▸ | KMT2A | Q03164 | 12/20 | 0.99 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.99 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.99 |
| ▸ | TSHR | P16473 | 6/20 | 0.99 |
| ▸ | HBB | P68871 | 5/20 | 0.99 |
| ▸ | MAPT | P10636 | 5/20 | 0.99 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.99 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.99 |
| ▸ | USP2 | O75604 | 4/20 | 0.99 |
| ▸ | CASP1 | P29466 | 4/20 | 0.99 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.99 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.99 |
| ▸ | CASP7 | P55210 | 3/20 | 0.99 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.99 |
| ▸ | BLM | P54132 | 3/20 | 0.99 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.99 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.99 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.99 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isoreserpine SCHEMBL731599 | 0.99 | MEN1 (1.00) | MEN1KMT2AKDM4ETDP1TSHR | |
| Reserpine SCHEMBL14379427 | 0.99 | MEN1 (1.00) | MEN1KMT2AKDM4ETDP1TSHR | |
| Reserpine SCHEMBL1172973 | 0.99 | MEN1 (1.00) | MEN1KMT2AKDM4ETDP1TSHR | |
| Reserpine SCHEMBL15385127 | 0.99 | MEN1 (1.00) | MEN1KMT2AKDM4ETDP1TSHR | |
| Reserpine SCHEMBL12732449 | 0.99 | MEN1 (1.00) | MEN1KMT2AKDM4ETDP1TSHR | |
| Reserpine SCHEMBL8262666 | 0.99 | MEN1 (1.00) | MEN1KMT2AKDM4ETDP1TSHR | |
| Reserpine SCHEMBL4562878 | 0.99 | MEN1 (1.00) | MEN1KMT2AKDM4ETDP1TSHR | |
| Reserpine SCHEMBL5372164 | 0.99 | MEN1 (1.00) | MEN1KMT2AKDM4ETDP1TSHR | |
| Reserpine SCHEMBL22002247 | 0.99 | MEN1 (1.00) | MEN1KMT2AKDM4ETDP1TSHR | |
| Reserpine SCHEMBL20402680 | 0.99 | MEN1 (1.00) | MEN1KMT2AKDM4ETDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5328453-A | Method for enhancing transdermal drug delivery of electrical drug applicators | DRUG DELIVERY SYSTEMS INC. (US) | 1994-07-12 | — | — | US | claimed |
| US-20250381110-A1 | SKIN CARE COMPOSITION AND METHOD OF USING THE SAME | PROCTER & GAMBLE (US) | 2025-12-18 | — | — | US | disclosed |
| CN-112384223-B | Pharmaceutical composition containing poorly soluble basic agent | 中外制药株式会社 | 2024-08-27 | — | — | CN | disclosed |
| CN-118159274-A | Syrup preparation | 中外制药株式会社 | 2024-06-07 | — | — | CN | disclosed |
| CN-114846012-B | 2-isoindole-1, 3, 4-oxadiazole derivatives useful as HDAC6 inhibitors | 武田药品工业株式会社 | 2024-01-26 | — | — | CN | disclosed |
| US-10967023-B2 | Preparation of a chinese medicinal composition including ginseng, ginkgo leaf and stigma croci | SHINEWAY PHARMACEUTICAL GROUP LTD. (CN) | 2021-04-06 | — | — | US | disclosed |
| US-10874669-B2 | Neuroprotective agents for treatment of neurodegenerative diseases | WAYNE STATE UNIVERSITY (US) | 2020-12-29 | — | — | US | disclosed |
| US-20190328810-A1 | CHINESE MEDICINAL COMPOSITION FOR PREVENTING OR TREATING CARDIOVASCULAR AND CEREBROVASCULAR DISEASES OR DEMENTIA, AND PREPARATION METHOD AND USE THEREOF | SHINEWAY PHARMACEUTICAL GROUP LTD. (CN) | 2019-10-31 | — | — | US | disclosed |
| US-20190076426-A1 | NEUROPROTECTIVE AGENTS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | WAYNE STATE UNIVERSITY | 2019-03-14 | — | — | US | disclosed |
| US-20190038622-A1 | NEUROPROTECTIVE AGENTS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | WAYNE STATE UNIVERSITY | 2019-02-07 | — | — | US | disclosed |
| US-20170354700-A1 | CHINESE MEDICINAL COMPOSITION FOR PREVENTING OR TREATING CARDIOVASCULAR AND CEREBROVASCULAR DISEASES OR DEMENTIA, AND PREPARATION METHOD AND USE THEREOF | SHINEWAY PHARMACEUTICAL GROUP LTD. (CN) | 2017-12-14 | — | — | US | disclosed |
| US-9034877-B2 | Bifunctional/polyfunctional dopamine D2/D3 agonist as neuroprotective agents for treatment of neurodegenerative diseases | WAYNE STATE UNIVERSITY (US) | 2015-05-19 | — | — | US | disclosed |
| US-20120108815-A1 | BIFUNCTIONAL/POLYFUNCTIONAL DOPAMINE D2/D3 AGONIST AS NEUROPROTECTIVE AGENTS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | WAYNE STATE UNIVERSITY (US) | 2012-05-03 | — | — | US | disclosed |
| WO-2010123995-A1 | BIFUNCTIONAL/POLYFUNCTIONAL DOPAMINE D2/D3 AGONIST AS NEUROPROTECTIVE AGENTS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | WAYNE STATE UNIVERSITY (US) | 2010-10-28 | — | — | WO | disclosed |
| US-4080456-A | PARKINSON*S DISEASE | SCHERING AKTIENGESELLSCHAFT (DT) | 1978-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190076426-A1 | NEUROPROTECTIVE AGENTS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | SMN1; SMN2, PARK7, SNCA | SLC18A2 310/4885MEN1 305/4885KMT2A 2698/4885 |
| US-20190038622-A1 | NEUROPROTECTIVE AGENTS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | SMN1; SMN2, PARK7, SNCA | SLC18A2 310/4885MEN1 305/4885KMT2A 2698/4885 |
| US-20120108815-A1 | BIFUNCTIONAL/POLYFUNCTIONAL DOPAMINE D2/D3 AGONIST AS NEUROPROTECTIVE AGENTS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | DRD3, DRD2, SLC6A3 | SLC18A2 35/4885MEN1 1570/4885KMT2A 1722/4885 |
| US-10874669-B2 | Neuroprotective agents for treatment of neurodegenerative diseases | SMN1; SMN2, PARK7, SNCA | SLC18A2 310/4885MEN1 305/4885KMT2A 2698/4885 |
| US-20250381110-A1 | SKIN CARE COMPOSITION AND METHOD OF USING THE SAME | SQSTM1, BECN1, CUTA | SLC18A2 3225/4885MEN1 3254/4885KMT2A 3682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.